Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
1.020
-0.020 (-1.92%)
Dec 30, 2024, 4:00 PM EST - Market closed
Cue Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Revenue | 9.53 | 5.49 | 1.25 | 14.94 | 3.15 | 3.46 | Upgrade
|
| Revenue Growth (YoY) | 149.53% | 340.96% | -91.67% | 373.68% | -8.79% | 202.67% | Upgrade
|
| Cost of Revenue | 37.29 | 38.1 | 35.3 | 41.35 | 33.55 | 27.49 | Upgrade
|
| Gross Profit | -27.76 | -32.61 | -34.05 | -26.41 | -30.39 | -24.03 | Upgrade
|
| Selling, General & Admin | 17.88 | 19.39 | 19.45 | 17.31 | 14.65 | 12.74 | Upgrade
|
| Operating Expenses | 17.88 | 19.39 | 19.45 | 17.31 | 14.65 | 12.74 | Upgrade
|
| Operating Income | -45.64 | -51.99 | -53.5 | -43.71 | -45.04 | -36.77 | Upgrade
|
| Interest Expense | -1.15 | -1.25 | -0.71 | - | - | - | Upgrade
|
| Interest & Investment Income | 2.24 | 2.66 | 0.93 | 0.05 | 0.54 | 0.41 | Upgrade
|
| EBT Excluding Unusual Items | -44.55 | -50.58 | -53.29 | -43.67 | -44.5 | -36.36 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -0.08 | 0.07 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.06 | -0.16 | 0.28 | - | - | - | Upgrade
|
| Pretax Income | -44.61 | -50.73 | -53.01 | -43.67 | -44.58 | -36.29 | Upgrade
|
| Income Tax Expense | - | - | - | 0.5 | 0.21 | 0.41 | Upgrade
|
| Net Income | -44.61 | -50.73 | -53.01 | -44.16 | -44.78 | -36.7 | Upgrade
|
| Net Income to Common | -44.61 | -50.73 | -53.01 | -44.16 | -44.78 | -36.7 | Upgrade
|
| Shares Outstanding (Basic) | 50 | 46 | 36 | 31 | 29 | 22 | Upgrade
|
| Shares Outstanding (Diluted) | 50 | 46 | 36 | 31 | 29 | 22 | Upgrade
|
| Shares Change (YoY) | 13.18% | 28.35% | 13.95% | 9.05% | 30.16% | 9.48% | Upgrade
|
| EPS (Basic) | -0.90 | -1.11 | -1.49 | -1.41 | -1.56 | -1.66 | Upgrade
|
| EPS (Diluted) | -0.90 | -1.11 | -1.49 | -1.41 | -1.56 | -1.66 | Upgrade
|
| Free Cash Flow | -38.32 | -39.96 | -41.98 | -39.75 | -33.09 | -30.84 | Upgrade
|
| Free Cash Flow Per Share | -0.77 | -0.87 | -1.18 | -1.27 | -1.15 | -1.40 | Upgrade
|
| Gross Margin | -291.24% | - | - | -176.73% | - | - | Upgrade
|
| Operating Margin | -478.80% | -947.03% | -4297.35% | -292.56% | -1427.96% | -1063.21% | Upgrade
|
| Profit Margin | -468.02% | -924.10% | -4257.83% | -295.56% | -1419.79% | -1061.18% | Upgrade
|
| Free Cash Flow Margin | -402.05% | -727.89% | -3371.65% | -266.04% | -1049.01% | -891.85% | Upgrade
|
| EBITDA | -45.23 | -51.44 | -52.58 | -42.45 | -43.99 | -35.96 | Upgrade
|
| EBITDA Margin | - | - | - | -284.14% | - | - | Upgrade
|
| D&A For EBITDA | 0.41 | 0.56 | 0.92 | 1.26 | 1.06 | 0.81 | Upgrade
|
| EBIT | -45.64 | -51.99 | -53.5 | -43.71 | -45.04 | -36.77 | Upgrade
|
| EBIT Margin | - | - | - | -292.56% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.